| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial
|
Pastorino, U.
|
|
|
33 |
4 |
p. 395-405
|
artikel
|
| 2 |
Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing
|
Terraf, P.
|
|
|
33 |
4 |
p. 426-433
|
artikel
|
| 3 |
Concomitant type 2 diabetes mellitus (T2DM) in metastatic melanoma patients could be related to lower level of LAG-3: a transcriptomic analysis of a retrospective cohort
|
Mallardo, D.
|
|
|
33 |
4 |
p. 445-447
|
artikel
|
| 4 |
Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer”
|
Novello, S.
|
|
|
33 |
4 |
p. 454
|
artikel
|
| 5 |
Corrigendum to “589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)”
|
Perez-Navarro, E.
|
|
|
33 |
4 |
p. 455
|
artikel
|
| 6 |
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
|
Subbiah, V.
|
|
|
33 |
4 |
p. 406-415
|
artikel
|
| 7 |
Editorial Board
|
|
|
|
33 |
4 |
p. iii
|
artikel
|
| 8 |
External control arms in oncology: current use and future directions
|
Mishra-Kalyani, P.S.
|
|
|
33 |
4 |
p. 376-383
|
artikel
|
| 9 |
Improving access to immunotherapy in low- and middle-income countries
|
Patel, A.
|
|
|
33 |
4 |
p. 360-361
|
artikel
|
| 10 |
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
|
Geyer, C.E.
|
|
|
33 |
4 |
p. 384-394
|
artikel
|
| 11 |
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study
|
Gazzah, A.
|
|
|
33 |
4 |
p. 416-425
|
artikel
|
| 12 |
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients
|
Chen, J.
|
|
|
33 |
4 |
p. 434-444
|
artikel
|
| 13 |
Table of Contents
|
|
|
|
33 |
4 |
p. i-ii
|
artikel
|
| 14 |
Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Oldenburg, J.
|
|
|
33 |
4 |
p. 362-375
|
artikel
|
| 15 |
The use of patient-reported outcomes (PROs) in cancer care: a realistic strategy
|
Minvielle, E.
|
|
|
33 |
4 |
p. 357-359
|
artikel
|
| 16 |
Too much for some and too little for others
|
Mercadante, S.
|
|
|
33 |
4 |
p. 445
|
artikel
|
| 17 |
VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
|
Paz-Ares, L.
|
|
|
33 |
4 |
p. 451-453
|
artikel
|
| 18 |
VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer
|
Vergote, I.B.
|
|
|
33 |
4 |
p. 448-450
|
artikel
|
Tijdschrift beschrijving